10x Genomics Earnings & Forecasts

10x Genomics (TXG) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

분기별 실적 서프라이즈 금액

회계 분기	보고된 날짜	실제 EPS	예상 EPS	놀라다 %
Q2	Aug 6, 2026	$-0.14	$-0.06	-133.3 %
Q1	May 7, 2026	$-0.10	$-0.10	0.00 %
Q4	Feb 12, 2026	$-0.13	$-0.10	-30.0 %
Q3	Nov 6, 2025	$-0.22	$-0.15	-46.7 %

Quarterly Revenue (Billions)

분기별 수익 깜짝 금액

회계 분기	보고된 날짜	실제 수익	예상 수익	놀라다 %
Q2	Aug 6, 2026	$151.00M	$146.68M	2.95 %
Q1	May 7, 2026	$150.84M	$146.38M	3.05 %
Q4	Feb 12, 2026	$166.03M	$159.13M	4.34 %
Q3	Nov 6, 2025	$149.00M	$142.47M	4.59 %

10x Genomics Guidance

10x Genomics (TXG)는 8월 6, 2026에 fiscal year 2026에 대한 가이던스를 마지막으로 발표했습니다. 회사는 해당 기간의 매출을 $610M - $630M 범위로 예상했습니다.

이전 가이던스와 비교하여 10x Genomics는 매출 전망치를 이전 범위인 상향 조정됨에서 $600M - $625M로 상향 조정했습니다.

10x Genomics은 22과 11월 2, 2022 사이에 8월 6, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 13 times and lowered it 5 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$-0.06	$-0.10	$-0.10	$-0.15
Actual	$-0.14	$-0.10	$-0.13	$-0.22
Surprise	-133.3%	0.00%	-30.0%	-46.7%
Revenue
Estimate	$146.7M	$146.4M	$159.1M	$142.5M
Actual	$151.0M	$150.8M	$166.0M	$149.0M
Surprise	+2.95%	+3.05%	+4.34%	+4.59%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$-0.07	$-0.05	$-0.08	$-0.15
Revenue
Consensus	$147.2M	$171.4M	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

PRO
10x Genomics Raises FY2026 Sales Guidance from $600.000M-$625.000M to $610.000M-$630.000M vs $613.851M Est

10x Genomics (NASDAQ:TXG) raises FY2026 sales outlook from $600.000 million-$625.000 million to $610.000 million-$630.000 million vs $613.851 million estimate.

Benzinga Newsdesk

PRO
10x Genomics Q2 EPS $(0.14) Beats $(0.24) Estimate, Sales $151.000M Beat $146.788M Estimate

10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.24) by 41.67 percent. This is a 150 percent decrease over earnings of $0.28 per share from the

Benzinga Newsdesk

PRO
10x Genomics Affirms FY2026 Sales Guidance of $600.000M-$625.000M vs $613.107M Est.

10x Genomics (NASDAQ:TXG) affirms FY2026 sales outlook from $600.000 million-$625.000 million to $600.000 million-$625.000 million vs $613.107 million estimate.

Benzinga Newsdesk

PRO
10x Genomics Q1 EPS $(0.10) Beats $(0.30) Estimate, Sales $150.843M Beat $146.355M Estimate.

10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.30) by 66.67 percent. This is a 64.29 percent increase over losses of $(0.28) per share from the

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

Earnings Scheduled For February 18, 2026

Benzinga Insights

10x Genomics Inc